Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Qiwi estimates loss on sale of Russian business at ₽37 billion

4/23/24 QIWI

QIWI reported for 2023 by IFRS

4/23/24 QIWI

Ministry of Energy agreed with the price of modernization of Vladivostok CHPP-2

4/23/24 HYDR

Cian moves to Russia

4/22/24 CIAN

Board of Directors of TGC-14 recommended that dividends be paid for 2023

4/22/24 TGKN

NKHP reported for 3 months of 2024 by RAS

4/22/24 NKHP

Nornickel in Q1 decreased nickel production by 10%

4/22/24 GMKN

SPB Exchange will allow trading sub-sanctioned brokers

4/22/24 SPBE

Nornickel to set up copper concentrate smelting facilities in China

4/22/24 GMKN

Softline starts expansion in Central Asian market

4/22/24 SOFL